Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) fell 15.4% during trading on Friday . The company traded as low as $27.06 and last traded at $27.06. 785 shares were traded during mid-day trading, an increase of 283% from the average session volume of 205 shares. The stock had previously closed at $31.99.
Swedish Orphan Biovitrum Price Performance
The stock has a fifty day moving average of $30.01 and a 200-day moving average of $29.24. The firm has a market capitalization of $9.63 billion, a price-to-earnings ratio of 25.53 and a beta of 0.44. The company has a current ratio of 1.04, a quick ratio of 0.71 and a debt-to-equity ratio of 0.31.
Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) last released its earnings results on Tuesday, April 29th. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.04. The business had revenue of $641.33 million for the quarter, compared to the consensus estimate of $644.12 million. Swedish Orphan Biovitrum had a net margin of 15.07% and a return on equity of 10.54%.
About Swedish Orphan Biovitrum
(
Get Free Report)
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.
Recommended Stories
Before you consider Swedish Orphan Biovitrum, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Swedish Orphan Biovitrum wasn't on the list.
While Swedish Orphan Biovitrum currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
